LOGIQ™ and Invenia™ ABUS 2.0

Elevating breast
ultrasound

Comprehensive solutions for a personalized
breast care from screening to treatment
monitoring
Configure now Contact us
LOGIQ Ultrasound & Invenia ABUS

Confidence in the management of breast disease with a personalized approach

Breast Cancer is the most diagnosed cancer in women. Every woman has her own story to tell and deserves her individual attention along the breast care pathway depending on her personal risk profile. Invenia ABUS and LOGIQ Ultrasound can become your trusted companion to help deliver a personalized breast care to your patients, across the care pathway.
Download the personalized breast care dedicated presentation

Personalized breast care with ultrasound

Breast video screen

Watch the breast care pathway solution

Screening icons en
Diagnosis staging icon en
Treatment icon en
Follow up icon en
Prof laszlo tabar
quotation mark
Hear from international breast Key Opinion Leader

“Radiologist who read mammograms need to know that every third breast cancer developing in dense breasts will be hidden by the dense fibro-glandular tissue. If only mammography is used in screening, we are going to miss these cancers that may develop to an advanced stage.”

Prof. László Tabár
Professor Emeritus of Radiology, Uppsala University, Medical Director Emeritus, Department of Mammography in Falun Central Hospital Sweden
Explore this clinical experience
Dr scaperrotta
quotation mark
Economic impact with ABUS

The implementation of supplemental ABUS screening for women with dense breasts in the Italian NHS could stimulate a significant decrease in the patients’ care and cancer treatment phase. Next to better patient care it will lead to a lower NHS resources absorption, with a potential total economic impact of 54 Million €.

Dr. Gianfranco Scaperrotta
Consultant Radiologist Chief of Breast Imaging Fondazione IRCCS - Istituto Nazionale dei Tumori Milano, Italy
Explore this clinical experience
Kinda douaidari 2
quotation mark
Koios DS™, AI in breast decision support

As potential future perspective of AI in breast ultrasound, I would expect could further classify more specific breast diseases, such as inflammatory breast masses, FA versus cellular FA, fibroplasia.

Dr. Kinda Douaidari
Director of the Breast Interventional Department
American Hospital
Dubai, EA
Explore this clinical experience
Dr vourtsis
quotation mark
ABUS, standardized and reproducible exams

ABUS is allowing the detection of noncalcified carcinomas that are obscured in mammography. Other major advantages include that it provides volumetric global visualization of the whole breast in x, y and z planes, [...] enabling batch reading and double reading of 3D ABUS and allowing a comparison with previous volumes.

Dr. Athina Vourtsis
Director and Founder of Diagnostic Mammography Center, Athens, Greece. Founding President of the Hellenic Breast Imaging Society. Member of the Medical Advisory Board of DenseBreast-Info.org
Explore this clinical experience
Dr fausto
quotation mark
Fusion Imaging in breast

The application of US/MRI Fusion Imaging makes it possible to detect a large number of additional breast lesions, occult at second-look ultrasound, and to biopsy a significant number of malignant lesions safely and irrespective of the distance from the skin or lesion position.

Dr. Alfonso Fausto
Consultant radiologist, Department of Diagnostic Imaging, Policlinico Santa Maria alle Scotte, Azienda Ospedaliera Universitaria Senese
Siena, Italy
Explore this clinical experience
Dr seitz
quotation mark
A great value in therapy monitoring

“ABUS as non-invasive and time-effective method has a great value in therapy monitoring in neoadjuvant treatment of breast cancer with a very high predictive value for complete response at the end of neoadjuvant chemotherapy“

PD, Dr. Stephan Seitz
Deputy Director Obstetrics and Gynecology,
Caritas-Krankenhaus St. Josef
Regensburg, Germany
Dr divijak
quotation mark
CEUS in therapy monitoring

Research indicates difference in contrast agent uptake dynamics between benign and malignant breast lesions. There is also probably a difference in contrast uptake before and after (successful) NAC.

Dr. Eugen Divjak
Consultant radiologist, Department of Radiology, University Hospital Dubrava
Zagreb, Croatia
Interested in requesting a quotation?

Configure my LOGIQ

Logiq e10 card
LOGIQ E10 Series
Logiq fortis card
LOGIQ Fortis
Logiq p series card
LOGIQ P Series

Have a question?
We would love to hear from you.

Contact us